Aphria Achieves a Critical Milestone in Germany — Will Its Stock Surge?

Investors in Aphria stock will welcome this new growth catalyst.

stocks rising

Image source: Getty Images

Canadian pot producer Aphria (TSX:APHA)(NASDAQ:APHA) has propped up its already outperforming stock after announcing a critical milestone in October. Investors in Aphria stock may look forward to better days after the company successfully made its first-ever shipment of medical cannabis to a new market: Germany.

Aphria’s new strategic milestone

The company finally shipped its first-ever medical marijuana product to Germany this month. In a press release published on Wednesday, company CEO, Irwin D. Simon was upbeat, stating that the shipment of dried flower products represented “another significant milestone for Aphria” that strengthened its position as a leading cannabis firm in the European Union.

The critical question from APHA stock investors today could be, “How is this a key achievement?”

One piece of APHA’s expansion strategy falls into place

More than half of Aphria’s revenue currently comes from Germany. But it’s in the form of low margin pharmaceuticals distribution revenue, with zero cannabis sales.

The Germany medical marijuana market is expected to be significantly larger than the Canadian medical and recreational markets combined. Pot companies from all over the world are scrambling for a piece of this most developed medical cannabis market in Europe. While Dutch and Canadian marijuana firms lead the pack, Aphria has not been a participant in the game.

Unfortunately, the Germany cannabis market hasn’t been accessible to APHA for years.

Tight production and import regulations shroud in EU Good Manufacturing Practices (EU GMP) certifications have been a hindrance to many interested suppliers. Aphria made a false start by getting cGMP certification from the U.S.A. around the time it acquired Nuuvera Inc. This was not the required certification for medical marijuana exports to European markets.

Finally, after receiving the correct certifications last year, the company has entered the high margin Germany medical cannabis market. Encouragingly, its subsidiary CC Pharma has distribution access to over 13,000 pharmacies in the European country.

Will Aphria’s stock price surge?

The news is good, but APHA stock price only increased by about 3% post the release. Something is missing in the company’s press release. The numbers are missing!

We know that finding a new growth market is necessary. Aphria ramped up its pot production this year after receiving new licenses. But the Canadian market has been too slow to grow. There’s a need to find new buyers for excess production. The company needs new markets.

Most noteworthy, cannabis exports to Germany will boost gross margins, sustain revenue growth, and allow the company to offload inventor, which is critical. A high production run rate is necessary for the company to keep its per-unit cash costs low. A recent 3,000-kilograms-per-year supply deal to Israel wasn’t enough to absorb excess inventory.

As highlighted above, details on how many grams of pot were actually shipped to Germany aren’t disclosed yet. Therefore, we can’t really tell if the latest milestone achievement has moved any needles yet.

That said, I would expect the latest export to be the first of many, even after the company completes its first facility in Germany for local production. This news piece was one of my expected growth drivers for Aphria stock. Shares should continue to rise as the company executes for growth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Investing

money cash dividends
Stocks for Beginners

Where to Invest $10,000 in April 2024

If you've already created a diversified portfolio and are looking for more options from a windfall, here is where I…

Read more »

data analyze research
Investing

The Ultimate TSX Stock to Buy With $1,000 Right Now

Brookfield Asset Management (TSX:BAM) is one of the best Canadian stocks to buy for those looking to put capital to…

Read more »

young woman celebrating a victory while working with mobile phone in the office
Dividend Stocks

3 CRA Benefits Most Canadians Can Grab in 2024

You can save on taxes by claiming the dividend tax credit on Fortis Inc (TSX:FTS) shares.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »